The disclosure relates to compounds of formula (I) which are formyl peptide 2 (FPR2) receptor agonists and / or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides methods and compositions for using the compounds for the treatment of, for example, atherosclerosis, heart failure, and related diseases.
展开▼